Scott Rocklage has spent many decades in the health management department, with his experiences earning him the approval of three U.S. New Drug Applications by the FDA, which include Omniscan, Teslascan, and Cubicin. In 2003, Rocklage joined 5AM Ventures as a Venture partner; in 2004, Rocklage became managing partner; and most recently, Rocklage has been bumped up to Founding partner of 5AM Ventures.
Rocklage started his journey by obtaining a BS in Chemistry at the University of California, Berkeley, and thereafter, getting his Ph.D. in Chemistry at the Massachusetts Institute of Technology, where he conducted research in the Laboratory of Richard R. Schrock. Earlier in Rocklage’s career, he has served as Chairman and CEO of Cubist Pharmaceuticals, President and CEO of Nycomed Salutar, and has held a variety of positions at Salutar and Catalytica. Rocklage now serves as Board Chairman of Rennovia, Kinestral, and Cidara, along with being Board Chairman of Relypsa and Novira (Johnson & Johnson). Learn more: http://5amventures.com/team/scott-m-rocklage-phd/
With his many projects and accomplishments, Rocklage has also issued a press release on the matter of Myotonic dystrophy type I, or DM I, a muscular dystrophy in adults, and how its growing worst each generation and there is no real effective treatment. Rocklage and Expansion Therapeutics have hatched a plan to advance small molecule medicines that target RNA and provide medication to those who don’t have any options. Expansion Therapeutics has already raised $55.3 million to finance RNA targeting medication. Expansion Therapeutics depend on science to treat RNA illnesses, such as Myotonic dystrophy type I, which have no real treatment at the moment. The ultimate goal is to find a cure for a disease that currently has no cure.